Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Fuji Pharma Co.,Ltd.. A complete text table follows the diagram.
Women’s health, biosimilars and global manufacturing lift operating profit, but a JPY3.5B securities valuation loss overwhelms the bottom line.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Loss On Valuation Of Investment Securities EL | 1 | 3.5B | 98.3% of reported total |
| Loss On Reduction Of Noncurrent Assets EL | 1 | 60M | 1.7% of reported total |
| Other & rounding | 1 | 1M | 0.0% of reported total |
| Extraordinary Loss | 2 | 3.6B | Reported six-month total · ¥3.6B |
| Profit before tax | 3 | 683M | Reported pretax result |
| A portfolio write-down masks the operating rebound | 3 | 2.9B | Women’s health, biosimilars and CMO growth nearly double operating profit, but a noncash investment loss pulls reported earnings sharply lower. |
| From | To | Value |
|---|---|---|
| Loss On Valuation Of Investment Securities EL | Extraordinary Loss | 3.5B |
| Loss On Reduction Of Noncurrent Assets EL | Extraordinary Loss | 60M |
| Other & rounding | Extraordinary Loss | 1M |
| Extraordinary Loss | Profit before tax | 683M |
| Extraordinary Loss | A portfolio write-down masks the operating rebound | 2.9B |